Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE - News) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs") today announced treatment of the first patient in the three-arm, placebo controlled, 60 patient Phase 1b Ampion-In -Knee (AIK) trial in Australia. The active ingredient in Ampion™ has extensive worldwide patent protection including composition of matter and use patents. Anti-inflammatory and autoimmune modulation drugs constitute one of the largest markets in the pharmaceutical industry... 
More...
More...